Dexmedetomidine implementation in pain management in the immediate postoperative period of cardiac surgery.
ENFERMERIA INTENSIVA 2019;
31:105-112. [PMID:
31694783 DOI:
10.1016/j.enfi.2019.03.006]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Revised: 03/25/2019] [Accepted: 03/29/2019] [Indexed: 11/16/2022]
Abstract
BACKGROUND
This study arose from the need to improve all tasks related to monitoring pain in post cardiac surgery patients.
OBJECTIVES
Checking and quantifying the pain suffered by patients undergoing cardiac surgery in the first 24hours of their stay in the intensive care unit (ICU), treated with Dexmedetomidine (Dex) as analgesic adjuvant, as well as their degree of sedation and the need for opiates such as rescue analgesia.
MATERIAL AND METHODS
Unicentric study, observational, descriptive, from April 2016 to September 2017. Both genders, all adult, undergoing cardiac surgery, operating theatre-extubated and Dex continuous infusion carriers. Pain degree level was evaluated by the Visual analogue Scale of Pain (VAS), from immediately post-surgery until 24hours from ICU entry and sedation degree, by the Richmond Sedation Agitation Scale (RASS), only while the Dex infusion lasted.
RESULTS
109 patients were included. The results obtained showed that the average pain suffered by patients during the first 24hours was .47 with standard deviation (SD) of 1.25; the average maximum pain experienced was 3.58 with a range of 0 to 8 and the RASS average was -.68 (SD: 0,80). In addition, 44.04% of the patients needed rescue opiates, although only 7.32% showed severe pain greater than 6.
CONCLUSIONS
The Dex infusion patients showed mild levels of pain, however, a small percentage, who must be taken into account, suffered severe pain.
Collapse